Title:
3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONE AS CXC-CHEMOKINE RECEPTOR LIGAND
Document Type and Number:
Japanese Patent JP2009179641
Kind Code:
A
Abstract:
To provide a compound controlling activity of the CXC chemokine receptor.
There is disclosed a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof which is useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer. There is also provided a pharmaceutical composition comprising the compound represented by formula (I) in combination with a pharmaceutically acceptable carrier or diluent or both. Further a method is provided for treating -chemokine-mediated diseases in mammal. The method comprises a step of administering an effective amount of compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof to a patient in need of such treatment.
Inventors:
TAVERAS ARTHUR G
AKI CYNTHIA J
BOND RICHARD W
CHAO JIANPING
DWYER MICHAEL
FERREIRA JOHAN A
CHAO JIANHUA
YU YOUNONG
BALDWIN JOHN J
KAISER BERND
LI GE
MERRITT J ROBERT
NELSON KINGSLEY H
ROKOSZ LAURA L
Application Number:
JP2009122594A
Publication Date:
August 13, 2009
Filing Date:
May 20, 2009
Assignee:
SCHERING CORP
PHARMACOPEIA DRUG DISCOVERY
International Classes:
C07D205/04; A61K31/136; C07D249/18; A61K31/166; A61K31/167; A61K31/18; A61K31/197; A61K31/198; A61K31/22; A61K31/223; A61K31/245; A61K31/275; A61K31/341; A61K31/343; A61K31/36; A61K31/381; A61K31/397; A61K31/40; A61K31/401; A61K31/4025; A61K31/41; A61K31/415; A61K31/416; A61K31/4192; A61K31/42; A61K31/422; A61K31/4245; A61K31/426; A61K31/427; A61K31/433; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/4412; A61K31/4425; A61K31/443; A61K31/445; A61K31/4453; A61K31/4525; A61K31/495; A61K31/496; A61K31/505; A61K31/506; A61K31/5375; A61K31/5377; A61K31/54; A61K31/55; A61K31/665; A61K45/00; A61P1/02; A61P1/04; A61P7/02; A61P9/10; A61P9/14; A61P11/00; A61P11/06; A61P13/12; A61P17/00; A61P17/06; A61P17/10; A61P19/02; A61P25/08; A61P25/28; A61P27/02; A61P31/04; A61P31/12; A61P31/18; A61P31/22; A61P33/06; A61P35/00; A61P37/06; A61P37/08; A61P39/02; A61P43/00; C07C225/20; C07C237/30; C07C237/44; C07C255/59; C07D207/08; C07D207/12; C07D207/14; C07D207/16; C07D207/34; C07D211/16; C07D211/22; C07D211/32; C07D211/46; C07D211/56; C07D211/60; C07D211/62; C07D213/38; C07D213/40; C07D213/56; C07D213/74; C07D213/76; C07D213/78; C07D213/81; C07D213/82; C07D213/89; C07D231/38; C07D231/44; C07D239/42; C07D239/47; C07D241/04; C07D257/06; C07D261/08; C07D265/30; C07D271/06; C07D277/06; C07D277/28; C07D285/06; C07D295/16; C07D295/18; C07D295/20; C07D295/22; C07D307/14; C07D307/52; C07D307/56; C07D307/78; C07D307/79; C07D307/81; C07D317/58; C07D333/20; C07D333/28; C07D333/36; C07D333/38; C07D401/04; C07D403/04; C07D405/04; C07D405/06; C07D405/12; C07D409/04; C07D409/12; C07D413/04; C07D413/12; C07D413/14; C07D417/12
Attorney, Agent or Firm:
Hidesaku Yamamoto
Takaaki Yasumura
Natsuki Morishita
